Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026

  • ID: 3984899
  • Report
  • Region: Global
  • 240 Pages
  • Roots Analysis
1 of 5
JAK Inhibitors Market is Expected to Grow at a CAGR of 23.5% Over the Next Decade

FEATURED COMPANIES

  • AB Science
  • Avexxin
  • Cyclacel
  • Iltoo Pharma
  • MorphoSys
  • Rigel Pharmaceuticals
  • MORE

Rheumatoid Arthritis (RA) is an autoimmune, inflammatory disorder wherein various components of the immune system begin to attack the body’s own cells and tissues. The disease is characterized by pain and swelling in and around the joints. It is a systemic disease and is known to affect several joints at the same time or different joints at different times. Hence, it is also termed as migratory or flitting polyarthritis. It has been estimated that RA affects over 1% of the world population and the overall risk of developing the disease is higher in women as compared to men.

Owing to the complex nature of the disease, there is no cure for RA yet. However, in the past few years, several synthetic and biological treatments have been designed to achieve minimum disease activity, decrease inflammation and pain, prevent joint damage and reduce the pace of disease progression. Treatment strategies have evolved from the use of salicylates to non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, synthetic disease modifying anti-rheumatic drugs (DMARDS), such as methotrexate (MTX), sulfasalazine and leflunomide, and gradually to biologic response modifiers.

MTX, one of the most popular synthetic DMARDs used to treat RA, was approved in 1988 and is generally used as a first line therapy. However, due to certain side-effects associated with treatment regimens involving higher doses of synthetic DMARDs and the fact that some patients fail to respond to such drugs have led to a shift in the market towards biologic therapies. The transition to biologic DMARDs has brought a significant change in this domain.

Biologics are a more targeted therapeutic option and result in significant reduction in disease symptoms and a decrease in disease activity in a large proportion of RA patients. Despite the known advantages, a subset of patients treated with biologics demonstrated the need of more innovative options, thereby prompting the drug developers to look for alternative therapeutic strategies.

Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. Apart from focusing on already established mechanisms of action, these companies are trying to offer novel and innovative treatment options. A number of collaborations and partnerships have been inked between various companies to progress the R&D and commercialization activities. As more such new generation molecules reach the late stages of clinical development and eventually get commercialized, the unmet need for efficacious therapies in this domain is likely to be satisfied to a large extent.

The Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026 report provides a comprehensive analysis of the current market landscape of rheumatoid arthritis based therapies (specifically, non - tumor necrosis factor (TNF) inhibitors) and an informed opinion on how the market is likely to evolve over the next decade. RA is known to substantially affect patients’ quality of life and is characterized by a more severe set of symptoms than those observed in patients with osteoarthritis.
 
The RA market is primarily populated by DMARDs that have been shown to alter the course of the disease and also improve radiographic outcomes. Biologic DMARDs including TNF inhibitors, such as HUMIRA® (USD 14 billion) , Enbrel® (USD 9 billion) , and REMICADE® (USD 6.6 billion) , are counted among the best-selling drugs in this market. In recent years, treatment options for RA have increased substantially with the development of several novel drugs/drug classes. In addition to TNF inhibitors, a number of novel biologic DMARDs, such as T-cell costimulatory blocking agents (Orencia®), B-cell depleting agents (Rituxan®), interleukin-6 (IL-6) inhibitors (Actemra®) and interleukin-1 (IL-1) receptor antagonists (Kineret®), have been approved over the past few years.
 
In 2012, Xeljanz®, the first oral non-biologic DMARD belonging to the janus kinase (JAK) inhibitors drug class was approved in the US. The drug generated revenues worth USD 523 million in 2015 alone. In comparison to traditional biologic DMARDs, which are delivered through injections or infusions, JAK inhibitors, or Jakinibs, are a new class of drugs that have been optimized for oral delivery.

It is also worth mentioning that a number of pharmaceutical companies are developing drugs with novel mechanisms of action, namely Bruton's tyrosine kinase (BTK) inhibitors, spleen tyrosine kinase (SYK) inhibitors, RANKL inhibitors and adenosine A3 receptor (A3AR) agonists, which (along with Jakinibs) represent the next generation of drugs designed to treat RA.

During the course of our study, we identified over 80 non-TNF inhibitors that are either already marketed or in various phases of development for the treatment of RA; of these, five drugs are currently marketed and four drugs (a JAK inhibitor, a RANKL inhibitor and two IL-6R inhibitors) are in the pre-registration stage. Overall, more than 60% of candidate drugs are currently under clinical development. Drug development efforts in this domain are being actively led by a mix of pharmaceutical giants, mid-sized companies and start-ups.

Among other things, the report features discussions on:

  • The current state of the market with respect to available drug classes, key players, phase of development of pipeline products (clinical and preclinical/discovery), route of administration, type of molecule and type of therapy.
  • An in-depth analysis comprising of schematic representations, including a grid analysis highlighting the distribution of pipeline, an overview of the landscape of industrial developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of RA therapeutics.
  • Detailed profiles of drugs that have been recently (post-2010) approved/marketed or are in the late stages of development (phase III and above).
  • Information on the mechanisms of action of novel drugs (non-TNF inhibitor) that are currently being investigated as potential treatment options for RA.
  • Detailed comparative analysis of the key clinical trial endpoints for drugs that are already marketed or are in phase III of development and insights on the clinical development programs designed for phase III drugs (active comparator trials, important primary endpoints and scale of trials).
  • A detailed analysis of the collaborations and agreements established amongst stakeholders in the past few years.
  • Emerging trends and a discussion on the popularity of non-TNF inhibitors on Twitter over the last few years.

In addition to the above mentioned analyses, the report also provides an estimate of the likely future size of the market for RA therapies. Our forecast model is built on an understanding of existing market trends and the likely future opportunity for JAK inhibitors, anti-interleukins (anti-ILs) and other novel drug classes. We have provided informed estimates on the expected future sales of marketed and late stage candidates under each category, highlighting their respective shares in the overall market over the next ten years.
 
The research, analysis and insights presented in this report are backed by a deep understanding of opinions gathered from secondary research. Actual figures have been sourced and analyzed from publicly available data. Unless otherwise specified, all financial figures are presented in USD.

Example Highlights

  • Although the DMARDs market is currently dominated by TNF inhibitors, non-TNF inhibitors, such as IL-6 inhibitors/IL-6R antagonists, IL-1 inhibitors, T-cell costimulation inhibitors, B-cell inhibitors and JAK inhibitors, have emerged as viable drug classes for the treatment of patients suffering from RA.
  • We came across over 80 drugs/therapies in the non-TNF inhibitors development pipeline; of these, 6% represent marketed molecules, while 11% of the pipeline molecules are either under review by the FDA or in phase III of clinical development. Over 30% of the molecules are in the preclinical/discovery stage.
  • JAK inhibitors and anti-ILs are the most popular drug classes in terms of the number of pipeline molecules that are in higher phases of development (pre-registration and phase III). Xeljanz® is the only JAK inhibitor that is currently commercially available; however, one such drug (baricitinib) is currently in the pre-registration stage, while three other JAK inhibitors (filgotinib, peficitinib and upadacitinib) are in phase III of clinical development. On the other hand, anti-ILs consist of two marketed (Actemra® and Kineret®) molecules, two in the pre-registration stage (sarilumab and sirukumab), six phase II product candidates (bimekizumab, clazakizumab, CNTO 6785, Dekavil, vobarilizumab and gerilimzumab) and four preclinical candidates.
  • Big biopharmaceutical players, namely Amgen, BMS, Roche/Genentech and Pfizer, currently hold the major share in the overall market with the maximum number of marketed drugs in this domain. There are several mid-sized and large firms, including (in alphabetical order) AbbVie, Amgen, Astellas Pharma, Daiichi Sankyo, Eli Lilly, Galapagos, Gilead Sciences, GSK, Incyte Corporation, Janssen, Regeneron Pharmaceuticals and Sanofi-Aventis, which have RA therapies in late stages of clinical development. Additionally, there are small-sized players that have captured a significant portion of the preclinical/discovery pipeline. Some of these players include (in alphabetical order) Acetylon Pharmaceuticals, Aegera Therapeutics, Arrien Pharmaceuticals, Asana BioSciences, Atlantic Bio Sci, Avexxin, CASI Pharmaceuticals, CJ HealthCare, Immune Response Biopharma, Oscotec, Peptinov, Principia Biopharma, RedHill Biopharma, SBI Biotech, TechnoPhage and Toleranzia.
  • A number of stakeholders in the non-TNF RA drugs market have entered into collaborations with other players. We came across close to 50 deals that have been signed over the last decade for various purposes, including product development and/or commercialization (70%), research (16%), manufacturing (6%), technology licensing (4%), acquisition (2%) and product distribution (2%). There are instances where a company has entered into more than one collaboration; examples of such players include (in alphabetical order) AbbVie, Ablynx, Bird Rock Bio, Can-Fite Biopharma, Chugai Pharmaceuticals, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Merck-Serono, MorphoSys and Roche.
  • In order to address the growing concerns related to patient compliance, drug developers have shifted their focus towards the development of orally administrable drugs. Of all pipeline molecules, over 50% are being developed as oral therapies.
  • The use of existing drugs as combination/add-on therapies has been shown to be associated with better outcomes and treatment effects compared to their use as monotherapies. In fact, 38% of the drugs in the clinical pipeline are being tested as add-on therapy/combination therapies. MTX is the preferred add-on/combination drug in most such clinical trials.
  • It is necessary to highlight that key patents protecting multiple approved drugs are set to expire in the coming years. This is likely to have a significant impact on the market’s growth in the mid-long term. However, we believe that the emergence of novel treatment options and the approval of late stage molecules is likely to balance the aforementioned decline. JAK inhibitors and non-TNF biologics are anticipated to capture the major share of the anti-TNFs market. Specifically, the JAK inhibitors market is expected to grow at a CAGR of 23.5% over the next decade.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science
  • Avexxin
  • Cyclacel
  • Iltoo Pharma
  • MorphoSys
  • Rigel Pharmaceuticals
  • MORE

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. Rheumatoid Arthritis: An Introduction
3.3. Rheumatoid Arthritis: Causes
3.4. Rheumatoid Arthritis: Diagnosis
3.5. Rheumatoid Arthritis: Currently Available Treatment Options
3.5.1. Analgesics
3.5.2. Non-Steroidal Anti-Inflammatory Drugs
3.5.3. Glucocorticoids
3.5.4. Disease Modifying Anti-Rheumatic Drugs
3.5.4.1. Conventional/Non-Biologic Disease Modifying Anti-Rheumatic Drugs
3.5.4.2. Biologic Disease Modifying Anti-Rheumatic Drugs
3.5.4.2.1. Tumor Necrosis Factor Inhibitors
3.5.4.2.2. Interleukin-1 Inhibitors
3.5.4.2.3. T-Cell Costimulation Inhibitors
3.5.4.2.4. B-Cell Inhibitors
3.5.4.2.5. Interleukin-6 Inhibitors

4. Market Overview
4.1. Chapter Overview
4.2. Rheumatoid Arthritis Therapeutics: Marketed and Clinical Pipeline
4.3. Rheumatoid Arthritis Therapeutics: Preclinical/Discovery Pipeline
4.4. Rheumatoid Arthritis Therapeutics: Distribution by Phase of Development
4.5. Rheumatoid Arthritis Therapeutics: Distribution by Drug Class
4.6. Rheumatoid Arthritis Therapeutics: Distribution by Route of Administration
4.7. Rheumatoid Arthritis Therapeutics: Distribution by Type of Molecule
4.8. Rheumatoid Arthritis Therapeutics: Distribution by Type of Therapy
4.9. Rheumatoid Arthritis Therapeutics: Distribution by Key Players
4.10. Rheumatoid Arthritis Therapeutics: List of Other Potential Candidates

5. Novel Drugs to Treat Rheumatoid Arthritis: Key Mechanisms of Action
5.1. Chapter Overview
5.2. Bruton's Tyrosine Kinase Inhibitors
5.3. Janus Kinase Inhibitors
5.4. Interleukin-17 Inhibitors
5.5. Granulocyte Macrophage-Colony Stimulating Factor Inhibitors
5.6. Stem Cell Therapies
5.7. Spleen Tyrosine Kinase Inhibitors
5.8. Chemokine Receptor Antagonists
5.9. Phospholipase A2 Inhibitors
5.10. Toll-Like Receptor Inhibitors

6. JAK Inhibitors
6.1. Chapter Overview
6.2. Xeljanz®/Tofacitinib (Pfizer)
6.2.1. Overview
6.2.2. Dosage Form, Regimen and Pricing
6.2.3. Historical Sales
6.2.4. Clinical Studies
6.2.5. Key Clinical Trial Results
6.2.5.1. Monotherapy
6.2.5.1.1. Oral Start
6.2.5.1.2. Oral Solo
6.2.5.2. Add-On/Combination Therapy
6.2.5.2.1. Oral Standard
6.2.5.2.2. Oral Step
6.2.5.2.3. Oral Scan
6.2.5.2.4. Oral Sync
6.2.6. Developer Overview (Pfizer)
6.2.6.1. Financial Performance
6.2.6.2. Collaborations
6.3. Baricitinib (Eli Lilly/Incyte Corporation)
6.3.1. Overview
6.3.2. Clinical Studies
6.3.3. Key Clinical Trial Results
6.3.3.1. Monotherapy/Add-On Therapy
6.3.3.1.1. RA-BEGIN
6.3.3.1.2. RA-BEYOND
6.3.3.2. Add-On/Combination Therapy
6.3.3.2.1. RA-BEAM
6.3.3.2.2. RA-BUILD
6.3.3.2.3. RA-BEACON
6.3.4. Developer Overview (Incyte Corporation/Eli Lilly)
6.3.4.1. Financial Performance
6.3.4.2. Collaborations
6.4. Filgotinib/GLPG0634 (Galapagos/Gilead Sciences)
6.4.1. Overview
6.4.2. Clinical Studies
6.4.3. Key Clinical Trial Results
6.4.3.1. Monotherapy
6.4.3.1.1. DARWIN 2
6.4.3.2. Add-on Therapy
6.4.3.2.1. DARWIN 1
6.4.3.2.2. NCT01384422
6.4.4. Developer Overview (Galapagos/Gilead Sciences)
6.4.4.1. Financial Performance
6.4.4.2. Collaborations
6.5. Peficitinib (Astellas Pharma)
6.5.1. Overview
6.5.2. Clinical Studies
6.5.3. Key Clinical Trial Results
6.5.3.1. Monotherapy
6.5.3.2. Add-On/Combination Therapy
6.5.4. Developer Overview (Astellas Pharma)
6.5.4.1. Financial Performance
6.5.4.2. Collaborations
6.6. Upadacitinib/ABT-494 (AbbVie)
6.6.1. Overview
6.6.2. Clinical Studies
6.6.3. Key Clinical Trial Results
6.6.3.1. Add-On Therapy/Combination Therapy
6.6.3.1.1. BALANCE-I
6.6.3.1.2. BALANCE-II
6.6.4. Developer Overview (AbbVie)
6.6.4.1. Financial Performance

7. Interleukin-6 Inhibitors
7.1. Chapter Overview
7.2. Sarilumab (Sanofi/Regeneron Pharmaceuticals)
7.2.1. Overview
7.2.2. Clinical Studies
7.2.3. Key Clinical Trial Results
7.2.3.1. Monotherapy
7.2.3.1.1. SARIL-RA-MONARCH
7.2.3.2. Add-On/Combination Therapy
7.2.3.2.1. SARIL-RA-MOBILITY
7.2.3.2.2. SARIL-RA-TARGET
7.2.3.2.3. SARIL-RA-ASCERTAIN
7.2.4. Developer Overview (Sanofi/Regeneron Pharmaceuticals)
7.2.4.1. Financial Performance
7.2.4.2. VelocImmune
7.2.4.3. Collaborations
7.3. Sirukumab (Johnson & Johnson/GSK)
7.3.1. Overview
7.3.2. Clinical Studies
7.3.3. Key Clinical Trial Results
7.3.3.1. SIRROUND-D
7.3.3.2. SIRROUND-H and SIRROUND-T Results
7.3.4. Developer Overview (Johnson & Johnson/GSK)
7.3.4.1. Financial Performance
7.3.4.2. Collaborations

8. Novel Drugs for Rheumatoid Arthritis
8.1. Chapter Overview
8.2. Piclidenoson/CF101 (Can-Fite Biopharma)
8.2.1. Overview
8.2.2. Clinical Studies
8.2.3. Key Clinical Trial Results
8.2.4. Developer Overview (Can-Fite Biopharma)
8.2.4.1. Financial Performance
8.2.4.2. Collaborations
8.3. Ravax™ (Immune Response BioPharma)
8.3.1. Overview
8.3.2. Clinical Studies
8.3.3. Key Clinical Trial Results
8.3.4. Developer Overview (Immune Response BioPharma)

9. Market Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Scope and Key Assumptions
9.4. Overall DMARDs Market for Rheumatoid Arthritis, 2016-2026 (USD Billion)
9.5. Overall JAK Inhibitors Market, 2016-2026 (USD Billion)
9.5.1. Xeljanz®/Tofacitinib (USD Million)
9.5.2. Baricitinib (USD Million)
9.5.3. Filgotinib (USD Million)
9.5.4. Peficitinib/ASP015K (USD Million)
9.5.5. Upadacitinib/ABT-494 (USD Million)
9.6. Overall Non-TNF Biologics Market, 2016-2026 (USD Billion)
9.6.1. Actemra®/Roactemra®/Tocilizumab/(USD Million)
9.6.2. Kineret®/Anakinra (USD Million)
9.6.3. Orencia®/Abatacept (USD Million)
9.6.4. Rituxan®/MabThera®/Rituximab (USD Million)
9.6.5. Sarilumab (USD Million)
9.6.6. Sirukumab (USD Million)
9.6.7. Ravax™ (USD Million)
9.7. Overall Other Novel Oral Therapies Market, 2016-2026 (USD Billion)
9.7.1. Piclidenoson/CF-101 (USD Million)

10. Key Insights
10.1. Chapter Overview
10.2. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Pipeline Analysis
10.3. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Developer Landscape
10.4. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Regional Distribution
10.5. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Active Comparator Trial Comparison10.6. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Patient Size Comparison
10.7. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Primary Endpoint Comparison

11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models/Agreements
11.3. Rheumatoid Arthritis: Recent Collaborations
11.3.1. Rheumatoid Arthritis: Mapping Collaborations
11.3.2. Rheumatoid Arthritis: Distribution of Partnerships by Year
11.3.3. Rheumatoid Arthritis: Distribution of Partnerships by Type of Model
11.3.4. Rheumatoid Arthritis: Distribution of Partnerships by Molecule
11.3.5. Rheumatoid Arthritis: Leading Collaborators

12. Emerging Trends on Social Media
12.1. Chapter Overview
12.2. Trends on Twitter
12.2.1. Rheumatoid Arthritis: Yearly Distribution of Tweets
12.2.2. Rheumatoid Arthritis: Highlights on Twitter
12.2.3. Rheumatoid Arthritis: Most Popular Drug Classes

13. Conclusion
13.1. Post the Paradigm Shift from Analgesics to Biologic DMARDS, the Rheumatoid Arthritis Market Continues to Evolve with the Emergence of Multiple Novel Drug Classes
13.2. With Five Marketed Product Candidates and Several Clinical and Preclinical Molecules, the non-TNF Inhibitors Pipeline Holds Significant Future Potential
13.3. Anti-Interleukins and JAK Inhibitors Have Emerged as Potential Therapeutic Options; BTK Inhibitors, SYK Inhibitors and GM-CSF Inhibitors are Amongst the Popular Novel Drug Classes Under Development
13.4. Emergence of Innovative Strategies Has Led to the Development of Stem Cell Therapies, Gene Therapies and Vaccines for the Treatment of RA
13.5. Oral Therapies are Likely to Emerge as Key Contributors in the Near Future
13.6. Combination Therapies Have been Shown to Offer Increased Health Benefits while Minimizing Adverse Effects Associated with Individual Therapeutic Classes
13.7. Big Pharmaceutical Companies Dominate the Current Rheumatoid Arthritis Space; Several Start-Ups/Small Companies Have Emerged
13.8. The Expected Launch of Late-Phase JAK Inhibitors and Anti-Interleukins in the Near Future is Likely to Intensify the Competition

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

List of Figures

Figure 3.1 Rheumatoid Arthritis: Currently Available Treatment Options
Figure 3.2 Therapeutic Interventions for Rheumatoid Arthritis: Marketed Analgesics
Figure 3.3 Therapeutic Interventions for Rheumatoid Arthritis: Marketed NSAIDs
Figure 3.4 Therapeutic Interventions for Rheumatoid Arthritis: Conventional/Non-Biologic DMARDs
Figure 3.5 Classification of Biologic DMARDs for Rheumatoid Arthritis Based on Mechanism of Action
Figure 4.1 Rheumatoid Arthritis Therapeutics: Distribution by Phase of Development
Figure 4.2 Rheumatoid Arthritis Therapeutics: Distribution by Drug Class
Figure 4.3 Rheumatoid Arthritis Therapeutics: Distribution by Route of Administration
Figure 4.4 Rheumatoid Arthritis Therapeutics: Distribution by Type of Molecule
Figure 4.5 Rheumatoid Arthritis Therapeutics: Distribution by Type of Therapy
Figure 4.6 Rheumatoid Arthritis Therapeutics: Distribution by Key Players
Figure 6.1 Tofacitinib: Historical Sales, FY2013 - Q3 FY2016 (USD Million)
Figure 6.2 Tofacitinib: Phase III Clinical Development Program
Figure 6.3 Tofacitinib as Add-On Therapy: Clinical Trial Results, ACR and DAS28-4 (ESR) Scores (% of Patients)
Figure 6.4 Tofacitinib as Add-On Therapy: Clinical Trial Results, Change from Baseline in HAQ-DI
Figure 6.5 Pfizer: Revenues, FY2011-Q3 FY 2016 (USD Billion)
Figure 6.6 Baricitinib: Phase III Clinical Development Program
Figure 6.7 Baricitinib: Clinical Trials Results, ACR Scores (% of Patients)
Figure 6.8 Incyte Corporation: Revenues, FY 2011-Q3 FY 2016 (USD Million)
Figure 6.9 Eli Lilly: Revenues, FY 2011-Q3 FY 2016 (USD Billion)
Figure 6.10 Filgotinib: Phase III Clinical Development Program
Figure 6.11 Filgotinib: Clinical Trial Results, ACR Scores (% of Patients)
Figure 6.12 Galapagos: Revenues, FY 2012-Q3 FY2016 (EUR Million)
Figure 6.13 Gilead Sciences: Revenues, FY 2011-Q3 FY 2016 (USD Billion)
Figure 6.14 Peficitinib: Phase III Clinical Development Program
Figure 6.15 Peficitinib: Clinical Trial Results, ACR Scores (% of Patients)
Figure 6.16 Astellas Pharma: Revenues, FY2011-Q2 FY2016 (JPY Billion)
Figure 6.17 Upadacitinib: Phase III Clinical Development Program
Figure 6.18 Upadacitinib: Clinical Trial Results, ACR Scores (% of Patients)
Figure 6.19 AbbVie: Revenues, FY 2011-Q3 2016 (USD Billion)
Figure 7.1 Sarilumab: Phase III Clinical Development Program
Figure 7.2 Sarilumab: Clinical Trials Results, ACR Scores (% of Patients)
Figure 7.3 Sarilumab: Clinical Trials Results, Change in HAQ-DI Scores
Figure 7.4 Regeneron Pharmaceuticals: Revenues, FY2011-Q3 FY2016 (USD Billion)
Figure 7.5 Sanofi: Revenues, FY2011-Q3 FY2016 (EUR Billion)
Figure 7.6 Sirukumab: Phase III Clinical Development Program
Figure 7.7 Johnson & Johnson: Revenues, FY2011-Q3 FY2016 (USD Billion)
Figure 7.8 GSK: Revenues, FY2011-Q3 FY2016 (GBP Billion)
Figure 9.1 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Base Scenario)
Figure 9.2 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Base Scenario): Distribution by Type of Drug Class
Figure 9.3 JAK Inhibitors Market (USD Billion), 2016-2026 (Base Scenario)
Figure 9.4 Xeljanz®/Tofacitinib Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.5 Baricitinib Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.6 Filgotinib Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Figure 9.7 Peficitinib/ASP015K Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Figure 9.8 Upadacitinib/ABT-494 Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Figure 9.9 Non-TNF Biologics Market (USD Billion), 2016-2026 (Base Scenario)
Figure 9.10 Actemra®/Roactemra®/Tocilizumab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.11 Kineret®/Anakinra Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.12 Orencia®/Abatacept Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.13 Rituxan®/MabThera®/ Rituximab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.14 Sarilumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.15 Sirukumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.16 Ravax™ Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.17 Overall Other Novel Oral Therapies Market (USD Billion), 2018-2026 (Base Scenario)
Figure 9.18 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Figure 10.1 Rheumatoid Arthritis Therapeutics Grid Analysis: Distribution by Drug Class, Type of Molecule and Phase of Development
Figure 10.2 Rheumatoid Arthritis Therapeutics Developer Landscape: Distribution by Developer and Phase of Development
Figure 10.3 Rheumatoid Arthritis Therapeutics Regional Analysis: Distribution by Company Location and Phase of Development
Figure 10.4 Rheumatoid Arthritis Therapeutics Clinical Trial Analysis: Distribution by Active Comparator
Figure 10.5 Rheumatoid Arthritis Therapeutics Clinical Trial Analysis: Distribution by Scale of Phase III Program
Figure 10.6 Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Distribution by Primary Endpoints
Figure 11.1 Rheumatoid Arthritis Therapeutics Collaboration Landscape: Distribution by Collaborators, Type and Year of Collaboration
Figure 11.2 Rheumatoid Arthritis: Cumulative Distribution of Partnerships by Year
Figure 11.3 Rheumatoid Arthritis: Distribution of Partnerships by Type of Model
Figure 11.4 Rheumatoid Arthritis: Distribution of Partnerships by Molecules
Figure 11.5 Rheumatoid Arthritis: Leading Collaborators
Figure 12.1 Rheumatoid Arthritis Social Media Analysis: Yearly Distribution of Tweets, January 2013 - July 2016
Figure 12.2 Rheumatoid Arthritis Social Media Analysis: Highlights on Twitter, January 2013- July 2016
Figure 12.3 Rheumatoid Arthritis Social Media Analysis: Twitter, Most Popular Drug Classes, January 2013- July 2016
Figure 13.1 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class

List of Tables

Table 3.1 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
Table 3.2 Therapeutic Interventions for Rheumatoid Arthritis: Marketed Corticosteroids
Table 3.3 Therapeutic Interventions for Rheumatoid Arthritis: Marketed Biologics
Table 4.1 Rheumatoid Arthritis Therapeutics: Marketed and Clinical Pipeline
Table 4.2 Rheumatoid Arthritis Therapeutics: Preclinical Pipeline
Table 4.3 Rheumatoid Arthritis Therapeutics: List of Potential Candidates
Table 5.1 Key Mechanisms of Action: List of Drugs Under Development
Table 6.1 Tofacitinib: Clinical Trials
Table 6.2 Tofacitinib: Clinical Trial Endpoints, Phase IV Trials
Table 6.3 Tofacitinib as Monotherapy: Clinical Trial Endpoints, Phase III Trials
Table 6.4 Tofacitinib as an Add-On Therapy: Clinical Trial Endpoints, Phase III Studies
Table 6.5 ORAL Start: Clinical Trial Results
Table 6.6 ORAL Solo: Clinical Trial Results
Table 6.7 ORAL Standard: Clinical Trial Results
Table 6.8 Oral Step: Clinical Trial Results
Table 6.9 ORAL Scan: Clinical Trial Results
Table 6.10 ORAL SYNC: Clinical Trial Results
Table 6.11 Baricitinib: Clinical Trials
Table 6.12 Baricitinib: Clinical Trial Endpoints
Table 6.13 RA-BEGIN: Clinical Trial Results
Table 6.14 RA-BEAM: Clinical Trial Results
Table 6.15 RA-BUILD: Clinical Trial Results
Table 6.16 RA-BEACON: Clinical Trial Results
Table 6.17 Filgotinib: Clinical Trials
Table 6.18 Filgotinib: Clinical Trial Endpoints
Table 6.19 DARWIN-2: Clinical Trial Results
Table 6.20 DARWIN-1: Clinical Trial Results
Table 6.21 NCT01384422: Clinical Trial Results
Table 6.22 Peficitinib: Clinical Trials
Table 6.23 Peficitinib: Clinical Trial Endpoints
Table 6.24 NCT01649999: Clinical Trial Results
Table 6.25 NCT01565655: Clinical Trial Results
Table 6.26 NCT01554696 Clinical Trial Results
Table 6.27 Upadacitinib: Clinical Trials
Table 6.28 Upadacitinib: Clinical Trial Endpoints
Table 6.29 BALANCE I: Clinical Trial Results
Table 6.30 BALANCE II: Clinical Trial Results
Table 7.1 Sarilumab: Clinical Trials
Table 7.2 Sarilumab as Monotherapy: Clinical Trial Endpoints
Table 7.3 Sarilumab as Add-On/Combination Therapy: Clinical Trial Endpoints
Table 7.4 SARIL-RA-MONARCH: Clinical Trial Results
Table 7.5 SARIL-RA-MOBILITY: Clinical Trial Results
Table 7.6 SARIL-RA-TARGET: Clinical Trial Results
Table 7.7 SARIL-RA-ASCERTAIN: Clinical Trial Results
Table 7.8 Sirukumab: Clinical Trials
Table 7.9 Sirukumab: Clinical Trial Endpoints
Table 7.10 SIRROUND-D: Clinical Trial Results
Table 8.1 Piclidenoson: Clinical Trials
Table 8.2 Piclidenoson: Clinical Trial Endpoints
Table 8.3 Ravax™: Clinical Trials
Table 8.4 Ravax™: Clinical Trial Endpoints
Table 9.1 Rheumatoid Arthritis Therapeutics Market: List of Forecasted Molecules
Table 9.2 Non-TNF Biologics: Molecules in Early/Mid-Stage Clinical Development
Table 9.3 Novel Oral Therapies: Molecules in Early/Mid-Stage Clinical Development
Table 11.1 Rheumatoid Arthritis: Recent Collaborations
Table 14.1 Rheumatoid Arthritis Therapeutics: Distribution by Phase of Development
Table 14.2 Rheumatoid Arthritis Therapeutics: Distribution by Drug Class
Table 14.3 Rheumatoid Arthritis Therapeutics: Distribution by Route of Administration
Table 14.4 Rheumatoid Arthritis Therapeutics: Distribution by Type of Molecule
Table 14.5 Rheumatoid Arthritis Therapeutics: Distribution by Type of Therapy
Table 14.6 Rheumatoid Arthritis Therapeutics: Distribution by Key Player
Table 14.7 Tofacitinib: Historical Sales, FY2013-Q3 FY 2016 (USD Million)
Table 14.8 Pfizer: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.9 Incyte Corporation: Revenues, FY2011-Q3 FY2016 (USD Million)
Table 14.10 Eli Lilly: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.11 Galapagos: Revenues, FY2012-Q3 FY2016 (EUR Million)
Table 14.12 Gilead Sciences: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.13 Astellas Pharma: Revenues, FY2011-Q2 FY2016 (JPY Billion)
Table 14.14 AbbVie: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.15 Regeneron Pharmaceuticals: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.16 Sanofi: Revenues, FY2011-Q3 FY2016 (EUR Billion)
Table 14.17 Johnson & Johnson: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.18 GSK: Revenues, FY2011-Q3 FY2016 (GBP Billion)
Table 14.19 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Optimistic Scenario)
Table 14.20 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Base Scenario)
Table 14.21 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Conservative Scenario)
Table 14.22 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Optimistic Scenario): Distribution by Type of Drug Class
Table 14.23 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Base Scenario): Distribution by Type of Drug Class
Table 14.24 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Conservative Scenario): Distribution by Type of Drug Class
Table 14.25 JAK Inhibitors Market (USD Billion), 2016-2026 (Optimistic Scenario)
Table 14.26 JAK Inhibitors Market (USD Billion), 2016-2026 (Base Scenario)
Table 14.27 JAK Inhibitors Market (USD Billion), 2016-2026 (Conservative Scenario)
Table 14.28 Xeljanz®/Tofacitinib Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.29 Xeljanz®/Tofacitinib Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.30 Xeljanz®/Tofacitinib Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.31 Baricitinib Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.32 Baricitinib Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.33 Baricitinib Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.34 Filgotinib Sales Forecast (USD Million), 2019-2026 (Optimistic Scenario)
Table 14.35 Filgotinib Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Table 14.36 Filgotinib Sales Forecast (USD Million), 2019-2026 (Conservative Scenario)
Table 14.37 Peficitinib Sales Forecast (USD Million), 2018-2026 (Optimistic Scenario)
Table 14.38 Peficitinib Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Table 14.39 Peficitinib Sales Forecast (USD Million), 2018-2026 (Conservative Scenario)
Table 14.40 Upadacitinib/ABT-494 Sales Forecast (USD Million), 2019-2026 (Optimistic Scenario)
Table 14.41 Upadacitinib/ABT-494 Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Table 14.42 Upadacitinib/ABT-494 Sales Forecast (USD Million), 2019-2026 (Conservative Scenario)
Table 14.43 Non-TNF Biologics Market (USD Billion), 2016-2026 (Optimistic Scenario)
Table 14.44 Non-TNF Biologics Market (USD Billion), 2016-2026 (Base Scenario)
Table 14.45 Non-TNF Biologics Market (USD Billion), 2016-2026 (Conservative Scenario)
Table 14.46 Actemra®/Roactemra®/Tocilizumab Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.47 Actemra®/Roactemra®/Tocilizumab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.48 Actemra®/Roactemra®/Tocilizumab Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.49 Kineret®/Anakinra Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.50 Kineret®/Anakinra Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.51 Kineret®/Anakinra Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.52 Orencia®/Abatacept Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.53 Orencia®/Abatacept Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.54 Orencia®/Abatacept Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.55 Rituxan®/MabThera®/Rituximab Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.56 Rituxan®/MabThera®/Rituximab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.57 Rituxan®/MabThera®/Rituximab Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.58 Sarilumab Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.59 Sarilumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.60 Sarilumab Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.61 Sirukumab Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.62 Sirukumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.63 Sirukumab Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.64 Ravax™ Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.65 Ravax™ Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.66 Ravax™ Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.67 Overall Other Novel Oral Therapies Market (USD Billion), 2020-2026 (Optimistic Scenario)
Table 14.68 Overall Other Novel Oral Therapies Market (USD Billion), 2020-2026 (Base Scenario)
Table 14.69 Overall Other Novel Oral Therapies Market (USD Billion), 2020-2026 (Conservative Scenario)
Table 14.70 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Optimistic Scenario)
Table 14.71 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Table 14.72 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Conservative Scenario)
Table 14.73 Rheumatoid Arthritis: Cumulative Distribution of Partnerships by Year
Table 14.74 Rheumatoid Arthritis: Distribution of Partnerships by Type of Model
Table 14.75 Rheumatoid Arthritis: Distribution of Partnerships by Molecule
Table 14.76 Rheumatoid Arthritis: Leading Collaborators
Table 14.77 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class (Optimistic Scenario)
Table 14.78 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class (Base Scenario)
Table 14.79 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class (Conservative Scenario)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AB Science
  • Avexxin
  • Cyclacel
  • Iltoo Pharma
  • MorphoSys
  • Rigel Pharmaceuticals
  • MORE

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For most of our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.
 
The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
 
Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of novel RA drugs in the coming decade.
 
Chapter 3 provides a general introduction to RA, highlighting all associated symptoms and complications. It also includes a detailed classification and overview of mechanisms of action of the various therapeutic interventions that are currently available for the treatment of RA. These include both conventional and emerging therapies.
 
Chapter 4 provides a comprehensive overview of the current landscape of the RA market. It includes information on over 80 molecules that fall under non-TNF inhibitor drug classes. Some of these are approved and already available in different regions across the globe. The rest are currently in various stages of preclinical/clinical development. The chapter presents an analysis of the pipeline molecules on the basis of their current phase of development, respective mechanisms of action, route of administration, type of therapy, type of molecule and key players involved in their development. It also provides a list of potential candidates for the treatment of RA based on their respective mechanisms of action.
 
Chapter 5 provides a brief introduction to the novel interventions that are currently being investigated as potential treatment options for RA. It provides information on their respective mechanisms of action and lists the pipeline molecules that are being developed under each drug class.
 
Chapter 6 contains detailed profiles of the recently approved and late stage (phase III and above) JAK inhibitors. Each profile features a general overview of the drug and provides information on additional aspects, such as recent sales (for marketed drugs), information on clinical trials and key trial endpoints, clinical trial results, a brief history of the developer, and the collaborations and partnerships that have been inked related to the particular drug/drug candidate.
 
Chapter 7 contains detailed profiles of late stage (phase III and above) anti-ILs. Each profile features a general overview of the drug and provides information on additional aspects, such as recent sales (for marketed drugs), information on clinical trials and key trial endpoints, clinical trial results, a brief history of the developer, and the collaborations and partnerships that have been inked related to the particular drug/drug candidate.
 
Chapter 8 contains detailed profiles of late stage (phase III) drugs/therapies with novel mechanisms of action. Each profile features a general overview of the drug/therapy and provides information on additional aspects, such as recent sales (for marketed drugs), information on clinical trials and key trial endpoints, clinical trial results, a brief history of the developer, and the collaborations and partnerships that have been inked related to the particular drug/therapy candidate.
 
Chapter 9 provides a detailed analysis on the likely future size of the RA therapies market over the next decade. It presents comprehensive forecast scenarios for individual drug classes, including JAK inhibitors, anti-ILs and drugs with other novel mechanisms of action, which have molecules in late stages of development.
 
Chapter 10 is a compilation of certain key insights on RA therapies that we came across during the course of this study. It provides schematic representations highlighting the distribution of RA drugs by target class, type of molecule and the highest phase of development. The chapter also features an analysis of the landscape of developers (small, mid-sized and large companies) of RA drugs and the geographical presence of the most active players in this domain. It also presents a detailed comparative analysis on the key clinical trial endpoints for drugs that are marketed or are in phase III of clinical development. In addition, it includes an analysis of active comparator trials, highlighting the available drugs against which novel RA therapies are being compared in clinical trials, important primary endpoints being evaluated in the same and the scale (in terms of number of patients) of the phase III clinical program of the aforementioned drugs.
 
Chapter 11 presents a detailed analysis on the partnerships and agreements established between industry players in the last few years. Additionally, the chapter highlights the financial details of the agreements (wherever available). The chapter features a schematic representation of the collaborations on the basis of the year of establishment, the type of partnership model employed and the companies involved.
 
Chapter 12 provides an overview of emerging trends on social media related to RA drugs. It includes analytical data representing the popularity of RA drugs on Twitter from 2011 to H1-2016.
 
Chapter 13 summarizes the entire report. It presents the key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.
 
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.
 
Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Note: Product cover images may vary from those shown
5 of 5
  • AB Science
  • AbbVie
  • Abbott Laboratories
  • Acetylon Pharmaceuticals
  • Aclaris Therapeutics
  • Adverum Biotechnologies
  • Aegera Therapeutics
  • Alder BioPharmaceuticals
  • Allergan
  • Almac Group
  • Amgen
  • Antitope
  • ArGentis Pharmaceuticals
  • Arrien Pharmaceuticals
  • Arthrogen
  • Asahi Kasei Pharma Corporation
  • Asana BioSciences
  • Astellas Pharma
  • AstraZeneca
  • Atlantic Bio Sci
  • Avexxin
  • Bayer HealthCare
  • BeiGene
  • Biogen Idec
  • Bird Rock Bio
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CASI Pharmaceuticals
  • CJ HealthCare
  • CMC Biologics
  • CONBA Pharmaceuticals
  • CSL
  • Can-Fite BioPharma
  • Centocor
  • ChemoCentryx
  • Chugai Pharmaceuticals
  • Cipher Pharmaceuticals
  • CleveXel Pharma
  • Commence Bio
  • Cyclacel
  • Daiichi Sankyo
  • Dendright Technology
  • Dynamix Pharmaceuticals
  • Eli Lilly
  • Eternity Bioscience
  • Evotec
  • Five Prime Therapeutics
  • Galapagos
  • Genentech
  • Genor BioPharma
  • Genosco
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Hanmi Pharmaceutical
  • HitGen
  • Hubei Bio Pharmaceutical Industry Technology Institute
  • Human Genome Sciences
  • Hutchison Medi Pharma
  • Iltoo Pharma
  • Immune Response Biopharma
  • Immunex
  • ImmusanT
  • Incyte Corporation
  • Innate Pharma
  • Intarcia Therapeutics
  • Janssen
  • Jiangsu Hengrui Medicine
  • KBP BioSciences
  • Kangstem Biotech
  • Kwangdong Pharmaceutical
  • Levolta Pharmaceuticals
  • Lexicon Pharmaceuticals
  • MacroGenics
  • MedImmune
  • Merck Serono
  • Mesoblast
  • Molecular Partners
  • MorphoSys
  • Morphotek
  • NapaJen Pharma
  • NovImmune
  • Novartis
  • Numab
  • Ono Pharmaceutical
  • Ortho Biotech
  • Oscotec
  • Peptinov
  • Pfizer
  • Philogen
  • Pivotal BioSciences
  • Portola Pharmaceuticals
  • Principia Biopharma
  • Protalex
  • RedHill Biopharma
  • Redx Pharma
  • Regeneron Pharmaceuticals
  • Rigel Pharmaceuticals
  • Roche 
  • Rottapharm Biotech
  • SBI Biotech
  • Sanofi-Aventis
  • Seikagaku Corporation
  • Sevion Therapeutics
  • Shanghai Institute of Materia Medica
  • Sorrento Therapeutics
  • Sun Pharma
  • Sunesis Pharmaceuticals
  • Taiho Pharmaceutical
  • Takeda Pharmaceuticals
  • TechnoPhage
  • The Veterans Affairs Medical Center of Memphis
  • TiGenix
  • Toleranzia
  • Translational Biosciences
  • UCB
  • University of Melbourne
  • University of Tennessee Health Science Center
  • Vitae Pharmaceuticals
  • Vitaeris
  • WuXi AppTec
  • Xencor
  • Yungjin Pharmaceutical
  • Ziarco Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll